Xtant Medical (NYSEAMERICAN:XTNT – Get Free Report) announced its quarterly earnings results on Tuesday. The medical device company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.05), FiscalAI reports. The company had revenue of $23.03 million for the quarter, compared to analyst estimates of $24.88 million. Xtant Medical had a return on equity of 3.68% and a net margin of 1.50%.
Here are the key takeaways from Xtant Medical’s conference call:
- Revenue and guidance declined: Q2 revenue fell to $23.0 million from $24.8 million on a pro forma basis, primarily due to weakness in legacy orthobiologics and amnio products. Xtant reduced full-year revenue guidance to $99 million–$103 million from $101 million–$105 million.
- Profitability weakened materially: Gross margin fell to 57.9% from 68.6%, while the company reported a $9.4 million net loss and a $2.7 million adjusted EBITDA loss, partly reflecting the $5 million Dilon fee, lower production efficiency, and inventory charges.
- HEMOBLAST® integration is progressing: The company recognized approximately $1.5 million of Q2 HEMOBLAST® revenue and expects transactional volume to exceed $1 million per month on a gross basis, with substantially all future sales expected to flow through Xtant’s contracts and distribution network.
- Expanded commercial reach and new products support future growth: Xtant integrated 17 Dilon salespeople and expanded its broader commercial team to more than 25 representatives, while reporting strong early traction for Trivium™ Shaped. Management expects these investments and cross-selling opportunities to accelerate biologics growth in the second half of 2026.
Xtant Medical Trading Down 6.1%
Shares of XTNT stock opened at $0.30 on Wednesday. The business’s fifty day moving average price is $0.43 and its 200 day moving average price is $0.51. The firm has a market capitalization of $42.15 million, a PE ratio of 30.08 and a beta of -0.13. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.34 and a quick ratio of 1.64. Xtant Medical has a 1-year low of $0.30 and a 1-year high of $0.95.
Analyst Upgrades and Downgrades
Read Our Latest Stock Report on XTNT
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new position in Xtant Medical in the second quarter valued at about $26,000. Wiregrass Investment Management LLC acquired a new position in Xtant Medical during the fourth quarter worth $81,000. Mink Brook Asset Management LLC raised its holdings in Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after purchasing an additional 60,997 shares during the last quarter. Renaissance Technologies LLC boosted its position in Xtant Medical by 28.8% during the fourth quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock worth $721,000 after purchasing an additional 205,945 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Xtant Medical by 4.6% during the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after purchasing an additional 104,159 shares in the last quarter. 69.33% of the stock is currently owned by institutional investors and hedge funds.
About Xtant Medical
Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.
The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.
Read More
- Five stocks we like better than Xtant Medical
- Hims & Hers’ Revenue Beat Came With a Profitability Problem
- A Westinghouse IPO Could Reset the Nuclear Stock Conversation
- Fastly’s Q2 Rally Shows Investors Are Buying the Edge AI Turnaround
- Paramount’s 30-Film Promise Puts AMC Back in the Box Office Conversation
Receive News & Ratings for Xtant Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical and related companies with MarketBeat.com's FREE daily email newsletter.
